Radiopharmaceuticals Sales

Radiopharmaceuticals Sales Market Outlook

The global radiopharmaceuticals market is projected to reach approximately USD 10 billion by 2035, exhibiting a robust compound annual growth rate (CAGR) of around 6.5% during the forecast period from 2025 to 2035. This growth is largely driven by the increasing prevalence of cancer and cardiovascular diseases, which necessitate advanced diagnostic and therapeutic solutions. Additionally, the rising demand for non-invasive procedures in diagnostics and therapeutic applications has significantly propelled the adoption of radiopharmaceuticals. Furthermore, advancements in radiopharmaceutical technology, such as the development of new radioisotopes and personalized medicine approaches, are expected to open new avenues for market expansion. The growing aging population, combined with an increase in healthcare expenditure worldwide, is also anticipated to contribute to the market's growth trajectory.

Growth Factor of the Market

The growth of the radiopharmaceuticals market can be attributed to several critical factors. First and foremost, the rise in the incidence of chronic diseases, particularly cancer, has necessitated innovative treatment solutions that radiopharmaceuticals provide. Additionally, there is a marked increase in research and development activities, resulting in novel product introductions that enhance diagnostic accuracy and treatment efficacy. The expanding applications of radiopharmaceuticals in personalized medicine further bolster market growth, allowing healthcare providers to tailor treatments based on individual patient profiles. The integration of advanced imaging technologies, such as PET and SPECT, with radiopharmaceuticals has also contributed to improved patient outcomes, thus driving demand. Lastly, supportive government initiatives and funding for nuclear medicine are expected to create a favorable environment for market players.

Key Highlights of the Market

• The global radiopharmaceuticals market is anticipated to witness a CAGR of 6.5% from 2025 to 2035.
• Oncology remains the leading application segment, driven by the rising incidence of cancer worldwide.
• North America is expected to hold a significant market share, owing to advanced healthcare infrastructure and high adoption rates of nuclear medicine.
• The diagnostic radiopharmaceuticals segment is projected to dominate the market, reflecting a growing preference for non-invasive diagnostic techniques.
• Technetium-99 is expected to be the most widely used ingredient type due to its extensive applications in various diagnostic procedures.

By Product Type

Diagnostic Radiopharmaceuticals:

Diagnostic radiopharmaceuticals are primarily used for imaging purposes in medical diagnostics. These products help in identifying various diseases and conditions, particularly in oncology, cardiology, and neurology. The widespread use of single-photon emission computed tomography (SPECT) and positron emission tomography (PET) scans has significantly contributed to the growth of this segment. With an increasing focus on early disease detection and the rising prevalence of chronic conditions, the demand for diagnostic radiopharmaceuticals is expected to witness substantial growth. Additionally, advancements in imaging technologies and the development of novel radiopharmaceuticals are anticipated to enhance diagnostic accuracy further, thus driving market expansion.

Therapeutic Radiopharmaceuticals:

Therapeutic radiopharmaceuticals play a crucial role in the treatment of various diseases, particularly cancers. These products are designed to deliver targeted radiation to malignant cells, thereby reducing side effects associated with conventional treatments like chemotherapy. The segment is gaining traction owing to the increasing adoption of targeted radionuclide therapy and the growing incidence of cancer globally. Innovations such as targeted alpha therapy (TAT) and beta-emitter therapies are expected to drive this market segment's growth. Furthermore, the integration of therapeutic and diagnostic radiopharmaceuticals, commonly referred to as theranostics, is enhancing personalized treatment options, further propelling market dynamics.

Alpha Emitters:

Alpha emitters are a class of therapeutic radiopharmaceuticals that emit alpha particles to induce lethal damage to targeted cancer cells. This method of treatment is advantageous due to its ability to deliver high doses of radiation to tumor cells while sparing surrounding healthy tissues. The increasing application of alpha emitters in treating prostate cancer and other localized tumors is driving demand in this segment. As clinical studies continue to demonstrate the efficacy of alpha emitter therapies, market expectations are heightened for innovative products. The development of novel alpha-emitting isotopes is also expected to enhance treatment options and improve patient outcomes.

Beta Emitters:

Beta emitters are widely utilized in both diagnostic and therapeutic applications. These radiopharmaceuticals emit beta particles and are primarily employed in the treatment of various cancers, including thyroid cancer. The segment is experiencing growth due to the rising adoption of beta-emitting isotopes, such as iodine-131, which are effective in treating specific malignancies. Moreover, advancements in beta-emitting therapies, such as the development of targeted beta therapies, are expected to enhance treatment precision and efficacy. The growing prevalence of thyroid-related disorders and the increasing number of approved beta-emitting radiopharmaceuticals are anticipated to further bolster this market segment.

Positron Emitters:

Positron emitters are primarily used in PET imaging and play a significant role in cancer diagnosis and treatment monitoring. Products utilizing positron-emitting isotopes, such as fluorine-18, are essential for imaging the metabolic activity of tumors. The increasing recognition of the importance of early cancer detection is driving the demand for positron emitters. Additionally, advancements in radiotracer development and ongoing research into the potential therapeutic applications of positron emitters are expected to enhance their market presence. The integration of positron emission tomography with other imaging modalities is also contributing to the growth of this segment.

By Application

Oncology:

Oncology is the largest application segment for radiopharmaceuticals, driven by the rising incidence of cancer worldwide. The ability of radiopharmaceuticals to provide precise imaging and targeted therapy has transformed cancer management practices. The growing aging population, along with lifestyle factors contributing to cancer development, has further augmented the need for effective diagnostic and therapeutic solutions. Innovations in targeted radionuclide therapies and ongoing clinical trials investigating new radiopharmaceuticals are expected to enhance treatment options. As healthcare providers increasingly prioritize personalized cancer treatment approaches, the oncology segment is projected to witness sustained growth in the radiopharmaceuticals market.

Cardiology:

Cardiology is another significant application area for radiopharmaceuticals, particularly in diagnosing and evaluating heart conditions. Radiopharmaceuticals used in this segment, such as technetium-99m, are instrumental in assessing myocardial perfusion and viability. The increasing prevalence of cardiovascular diseases and the rising demand for non-invasive imaging techniques are propelling the growth of radiopharmaceuticals in cardiology. Furthermore, ongoing advancements in nuclear imaging technology and growing awareness about the importance of early detection are expected to bolster the usage of radiopharmaceuticals in cardiovascular applications. The segment is anticipated to capture a larger share of the overall market as new imaging agents are introduced.

Neurology:

The application of radiopharmaceuticals in neurology is growing steadily, with increasing recognition of the role they play in diagnosing neurodegenerative disorders and other neurological conditions. Radiopharmaceuticals like fluorine-18 are widely used in PET imaging to evaluate brain functions and detect abnormalities associated with diseases like Alzheimer's and Parkinson's. The rising prevalence of neurological disorders, coupled with advancements in imaging technologies, is expected to drive demand in this segment. Moreover, ongoing research into developing new radiopharmaceuticals tailored for neurological applications is anticipated to enhance diagnostic capabilities and improve patient outcomes.

Endocrinology:

Endocrinology is an emerging application segment for radiopharmaceuticals, primarily in treating thyroid disorders. Iodine-131 is a well-known radiopharmaceutical used in the effective treatment of hyperthyroidism and thyroid cancer. The increasing incidence of thyroid-related diseases and the growing awareness about the benefits of radiopharmaceutical therapies are driving demand in this application area. Moreover, the potential for developing new radiopharmaceuticals to target other endocrine disorders presents significant growth opportunities. As the healthcare industry continues to explore the therapeutic potential of radiopharmaceuticals in endocrinology, this segment is expected to gain traction in the coming years.

By Distribution Channel

Hospitals:

The hospital segment remains the dominant distribution channel for radiopharmaceuticals, accounting for a significant share of the market. Hospitals typically operate advanced imaging and therapeutic equipment capable of utilizing radiopharmaceuticals effectively. The increasing number of cancer treatment centers and diagnostic imaging facilities within hospital networks is driving the demand for radiopharmaceuticals in this channel. Furthermore, hospitals provide comprehensive care, combining diagnostic services with therapeutic interventions, which enhances patient outcomes. As the healthcare sector continues to prioritize cancer care and advanced imaging technologies, hospitals will remain a crucial distribution channel for radiopharmaceuticals.

Diagnostic Centers:

Diagnostic centers are increasingly becoming pivotal in the distribution of radiopharmaceuticals due to the rising demand for specialized imaging services. These centers focus on providing advanced diagnostic solutions, including nuclear imaging, which is integral to various radiopharmaceutical applications. The growing trend of outpatient diagnostics and the increasing prevalence of chronic diseases are driving the expansion of diagnostic centers. Additionally, partnerships between radiopharmaceutical manufacturers and diagnostic centers are expected to enhance access to innovative imaging solutions. This collaboration is anticipated to foster the adoption of radiopharmaceuticals, thus contributing to the growth of this distribution channel.

Specialty Clinics:

Specialty clinics are also emerging as a significant distribution channel for radiopharmaceuticals, particularly those focused on oncology, cardiology, and neurology. These clinics provide targeted services that cater to specific patient needs, facilitating the use of radiopharmaceuticals for accurate diagnosis and effective treatments. The rise of precision medicine and the increasing emphasis on personalized care have amplified the demand for specialized clinics. As the healthcare landscape evolves, with more patients seeking specialized services, the role of specialty clinics in the distribution of radiopharmaceuticals is expected to grow, further diversifying market access.

Online Pharmacies:

Online pharmacies have started to gain traction in the distribution of radiopharmaceuticals, offering convenience and accessibility to patients. This channel facilitates the purchase of prescription medications, including radiopharmaceuticals, through digital platforms. The growing trend towards telemedicine and the increase in patient awareness regarding treatment options have propelled the adoption of online pharmacies. However, the distribution of radiopharmaceuticals through this channel is subject to stringent regulations and must comply with safety standards. As more patients embrace online healthcare solutions, the role of online pharmacies in the distribution of radiopharmaceuticals is anticipated to expand.

By Ingredient Type

Technetium-99:

Technetium-99m is the most widely used radioisotope in the radiopharmaceutical market, primarily utilized in diagnostic imaging. Its ability to provide high-resolution images with low radiation exposure has made it the go-to choice for a variety of procedures, including bone scans, cardiac imaging, and cancer diagnostics. The growing number of diagnostic procedures incorporating technetium-99m, combined with its wide availability, is expected to drive the demand for this ingredient type. The continuous advancements in production methods and the development of new technetium-99m-based radiopharmaceuticals are likely to further enhance its market presence.

Fluorine-18:

Fluorine-18 is a key radioisotope used in positron emission tomography (PET) imaging, particularly in oncology. Its high uptake by cancerous tissues allows for accurate detection and characterization of tumors. The increasing adoption of PET imaging techniques for cancer diagnosis and treatment monitoring is driving the demand for fluorine-18. Furthermore, ongoing research into developing new fluorine-18 labeled compounds for various applications is expected to expand its usage. As the emphasis on early cancer detection continues to grow, fluorine-18 is anticipated to play a vital role in shaping the future of radiopharmaceuticals.

Iodine-131:

Iodine-131 is primarily used in the treatment of thyroid disorders, including hyperthyroidism and thyroid cancer. Its ability to selectively target thyroid tissue while sparing healthy cells has made it a standard treatment option. The rising incidence of thyroid-related conditions is driving demand for iodine-131 in the market. Additionally, ongoing developments in radioiodine therapies are expected to enhance its therapeutic efficacy further. As healthcare providers increasingly recognize the value of radiopharmaceuticals in managing endocrine disorders, iodine-131 is anticipated to maintain its significance in this segment.

Gallium-68:

Gallium-68 is gaining popularity as a positron emitter in PET imaging, particularly for neuroendocrine tumors and prostate cancers. Its favorable physical properties and ability to target specific receptors make it a valuable addition to the radiopharmaceutical arsenal. The increasing prevalence of neuroendocrine tumors and the growing demand for personalized cancer therapies are driving the adoption of gallium-68. Moreover, ongoing research into developing gallium-68 labeled compounds for various diagnostic applications is expected to broaden its utilization. As the market for radiopharmaceuticals continues to evolve, gallium-68 is likely to emerge as a significant player.

By Region

The North American region is anticipated to hold a substantial share of the radiopharmaceuticals market, driven by advanced healthcare infrastructure, high adoption of nuclear medicine, and significant investment in research and development. The presence of leading market players and a strong focus on oncological and cardiovascular diagnostics further bolster market growth in this region. The increasing prevalence of chronic diseases, coupled with an aging population, has created a robust demand for radiopharmaceuticals in the North American market. Additionally, North America is projected to experience a CAGR of approximately 7% during the forecast period, indicating a strong growth trajectory.

In Europe, the radiopharmaceuticals market is also poised for significant growth, fueled by the rising incidence of cancer and cardiovascular diseases. The region benefits from well-established healthcare systems and a strong emphasis on advanced imaging technologies. Several European countries are investing heavily in nuclear medicine research, further propelling market dynamics. The growing awareness of the benefits of personalized medicine and the increasing availability of radiopharmaceuticals in diagnostic and therapeutic applications are expected to contribute to market growth in Europe. The market in this region is projected to reach USD 3 billion by 2035.

Opportunities

Opportunities in the radiopharmaceuticals market are abundant, particularly as advancements in technology and innovation continue to pave the way for new applications. One of the major opportunities lies in the development of theranostics, which combines diagnostic and therapeutic capabilities into a single radiopharmaceutical product. This approach allows for personalized treatment plans tailored to individual patient needs, significantly improving treatment outcomes. As research continues to unveil the potential of theranostic agents in various cancers, manufacturers have the opportunity to invest in the development of new compounds that can effectively target specific malignancies. Furthermore, collaborations between pharmaceutical companies, research institutions, and healthcare providers can facilitate the exploration of novel applications, thus expanding market horizons.

Another promising opportunity lies in the increasing demand for radiopharmaceuticals in emerging markets. As healthcare infrastructure improves in regions such as Asia-Pacific and Latin America, the accessibility and adoption of advanced medical technologies, including radiopharmaceuticals, are on the rise. Increasing healthcare expenditure in these regions, coupled with a growing prevalence of chronic diseases, presents a significant opportunity for market players to expand their geographic presence. Additionally, education and awareness initiatives focused on the benefits of nuclear medicine can stimulate demand, thus creating a favorable environment for growth. As companies strive to penetrate these emerging markets, tailored strategies that consider local regulations and market dynamics will be vital for success.

Threats

The radiopharmaceuticals market faces several threats that could impact its growth trajectory. One of the most significant challenges is the stringent regulatory environment governing the production and distribution of radiopharmaceuticals. Regulatory agencies require comprehensive safety and efficacy data, which can prolong the approval process for new products. This lengthy process may deter companies from investing in innovative radiopharmaceuticals or limit the introduction of new therapies. Additionally, the high costs associated with research and development, along with the increasing competition among market players, can pose financial risks. Companies may struggle to obtain the necessary funding to support their research initiatives and operational costs, creating a challenging landscape for new entrants.

Another potential threat to the radiopharmaceuticals market is the risk of supply chain disruptions, particularly concerning the sourcing of raw materials and isotopes required for production. Factors such as geopolitical tensions, natural disasters, or regulatory changes can adversely affect the supply chain, leading to shortages of critical radiopharmaceuticals in the market. Moreover, the increasing prevalence of alternative diagnostic and treatment modalities, such as molecular imaging technologies or targeted therapies, may lead to a decline in the reliance on radiopharmaceuticals, thereby impacting market growth. As the industry evolves, addressing these potential threats will be crucial for ensuring sustained market growth and stability.

Competitor Outlook

• GE Healthcare
• Siemens Healthineers
• Bristol Myers Squibb
• Telix Pharmaceuticals
• Pfizer Inc.
• Novartis AG
• Bracco Imaging S.p.A.
• Lantheus Medical Imaging, Inc.
• Cardinal Health, Inc.
• Curium Pharma
• Radiopharm Theranostics
• United Imaging Healthcare Co., Ltd.
• Jubilant Radiopharma
• IsoTherapeutics Group, LLC
• Nordion Inc. (a part of Sterigenics)

The competitive landscape of the radiopharmaceuticals market is characterized by a mix of established players and emerging companies, with a focus on innovation and technological advancements. Leading companies such as GE Healthcare and Siemens Healthineers dominate the market due to their extensive portfolios, advanced imaging technologies, and significant investments in research and development. These companies actively seek partnerships, collaborations, and mergers to enhance their product offerings and expand their market presence. The competitive environment is further intensified by the increasing number of new entrants focused on developing novel radiopharmaceuticals targeting specific therapeutic areas, particularly oncology and neurology.

As the market evolves, companies are prioritizing strategic collaborations and partnerships to enhance their research capabilities and expand their product pipelines. For instance, Bristol Myers Squibb and Novartis AG are leveraging their extensive research networks to develop innovative radiopharmaceuticals, particularly in oncology, where there is a significant unmet need. Additionally, companies such as Telix Pharmaceuticals and Lantheus Medical Imaging are focusing on targeted therapies and personalized medicine to differentiate their offerings in the market. The emphasis on creating more effective and safer radiopharmaceuticals will be a key driver of competition, as companies strive to gain a competitive edge in this growing market.

Furthermore, ongoing advancements in production technologies and the emergence of novel radiotracers are expected to reshape the competitive dynamics of the radiopharmaceuticals market. Companies investing in state-of-the-art manufacturing facilities and automated systems will be better positioned to meet the growing demand for radiopharmaceuticals while ensuring product quality and consistency. Curium Pharma and Jubilant Radiopharma are examples of companies actively expanding their production capabilities to cater to the increasing demand for radiopharmaceuticals globally. Overall, the competitive landscape is expected to remain dynamic, with companies continuously striving to innovate and adapt to the changing market conditions.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Novartis AG
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Pfizer Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Curium Pharma
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 GE Healthcare
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Bristol Myers Squibb
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Jubilant Radiopharma
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Siemens Healthineers
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Bracco Imaging S.p.A.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Cardinal Health, Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Telix Pharmaceuticals
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Radiopharm Theranostics
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 IsoTherapeutics Group, LLC
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Lantheus Medical Imaging, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 United Imaging Healthcare Co., Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Nordion Inc. (a part of Sterigenics)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Radiopharmaceuticals Sales Market, By Application
    • 6.1.1 Oncology
    • 6.1.2 Cardiology
    • 6.1.3 Neurology
    • 6.1.4 Endocrinology
    • 6.1.5 Others
  • 6.2 Radiopharmaceuticals Sales Market, By Product Type
    • 6.2.1 Diagnostic Radiopharmaceuticals
    • 6.2.2 Therapeutic Radiopharmaceuticals
    • 6.2.3 Alpha Emitters
    • 6.2.4 Beta Emitters
    • 6.2.5 Positron Emitters
  • 6.3 Radiopharmaceuticals Sales Market, By Ingredient Type
    • 6.3.1 Technetium-99
    • 6.3.2 Fluorine-18
    • 6.3.3 Iodine-131
    • 6.3.4 Gallium-68
    • 6.3.5 Others
  • 6.4 Radiopharmaceuticals Sales Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Diagnostic Centers
    • 6.4.3 Specialty Clinics
    • 6.4.4 Online Pharmacies
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Radiopharmaceuticals Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Radiopharmaceuticals Sales market is categorized based on

By Product Type

• Diagnostic Radiopharmaceuticals
• Therapeutic Radiopharmaceuticals
• Alpha Emitters
• Beta Emitters
• Positron Emitters

By Application

• Oncology
• Cardiology
• Neurology
• Endocrinology
• Others

By Distribution Channel

• Hospitals
• Diagnostic Centers
• Specialty Clinics
• Online Pharmacies
• Others

By Ingredient Type

• Technetium-99
• Fluorine-18
• Iodine-131
• Gallium-68
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• GE Healthcare
• Siemens Healthineers
• Bristol Myers Squibb
• Telix Pharmaceuticals
• Pfizer Inc.
• Novartis AG
• Bracco Imaging S.p.A.
• Lantheus Medical Imaging, Inc.
• Cardinal Health, Inc.
• Curium Pharma
• Radiopharm Theranostics
• United Imaging Healthcare Co., Ltd.
• Jubilant Radiopharma
• IsoTherapeutics Group, LLC
• Nordion Inc. (a part of Sterigenics)